Bio-Techne has announced a collaboration to distribute Spear Bio’s advanced SPEAR UltraDetect immunoassays worldwide, with an initial focus on the neurology research market. This partnership allows ...
MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling ...
Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific ...
Life sciences company Bio-Techne (NASDAQ:TECH) in Q3 CY2025, with sales falling 1% year on year to $286.6 million. Its non-GAAP profit of $0.42 per share was in line with analysts’ consensus estimates ...
Grants Bio-Techne expanded commercial rights to develop a portfolio of genetics products beyond the recently launched AmplideX® Nanopore Carrier Plus Kit Establishes a framework to define and propose ...
Partnership strengthens Bio-Techne's (TECH) leadership in AI-enabled protein innovation NovoBody™ Duo molecules offer multi-specific binding capabilities for advanced research and diagnostics ...
Bio-Techne (TECH) prevailed on another claim that Miltenyi Biotec KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne’s proprietary R&D Systems ...
We’re sorry, we are currently experiencing some issues, please try again later. Our team is working diligently to resolve the issue. Thank you for your patience and ...
Bio-Techne’s 21% return over the past six months has outpaced the S&P 500 by 10.9%, and its stock price has climbed to $62.36 ...
Bio-Techne Corp. closed 13.72% short of its 52-week high of $79.28, which the company achieved on February 5th.
More than 600,000 times, researchers have cited Bio-Techne Corp. in academic papers as a manufacturer of tools that helped in their search for new tests and treatments. The company, Minnesota's ...